Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Navigate: Correlations HPO
There is one clinical trial.
To date, the effects of SARS-Cov-2 (Covid-19) on the myocardium and the role it plays in the evolution towards an acute myocarditis are badly understood. The current pandemic of this emerging virus is an opportunity to assess the proportion of acute myocarditis attributable to SARS-Cov-2(Covid-19) and to assess the clinical, biological and imaging presentations, by means of a national prospective multicentre hospital registry of cases of acute myocarditis.
Description: Estimate at hospital discharge, over a period of 6 months, the evolution of the proportion of positive SARS-COV-2 cases among patients hospitalized for acute myocarditis in Intensive Cardiac Care Unit or Intensive Care Unit (polyvalent, surgical or medical), in the 19 hospitals participating in the study.
Measure: Evolution of the proportion of positive SARS-COV-2 cases. Time: 6 months.Description: Describe at the admission and during the treatment ultrasound characteristics of the acute myocarditis among the positive and negative SARS-Cov-2 patients of the myocarditis cohort; Echocardiographic parameters: Volumes (mm3)
Measure: Ultrasound characteristics. Time: 1 yearDescription: Describe at the admission and during the treatment ultrasound characteristics of the acute myocarditis among the positive and negative SARS-Cov-2 patients of the myocarditis cohort ; Echocardiographic parameters: diameters (mm)
Measure: Ultrasound characteristics. Time: 1 yearDescription: Describe at the admission and during the treatment ultrasound characteristics of the acute myocarditis among the positive and negative SARS-Cov-2 patients of the myocarditis cohort (Echocardiographic parameters: ventricular diastolic function (mm);
Measure: Ultrasound characteristics. Time: 1 yearDescription: Describe at the admission and during the treatment ultrasound characteristics of the acute myocarditis among the positive and negative SARS-Cov-2 patients of the myocarditis cohort (Echocardiographic parameters: ventricular systolic function (mm);
Measure: Ultrasound characteristics. Time: 1 yearDescription: Describe at the admission and during the treatment ultrasound characteristics of the acute myocarditis among the positive and negative SARS-Cov-2 patients of the myocarditis cohort ; Echocardiographic parameters: Left atrium volume (mm3);
Measure: Ultrasound characteristics. Time: 1 yearDescription: Describe at the admission and during the treatment ultrasound characteristics of the acute myocarditis among the positive and negative SARS-Cov-2 patients of the myocarditis cohort ; Echocardiographic parameters: Maximum velocity of tricuspid valve insufficiency;
Measure: Ultrasound characteristics. Time: 1 yearDescription: Describe at the admission and during the treatment ultrasound characteristics of the acute myocarditis among the positive and negative SARS-Cov-2 patients of the myocarditis cohort ; Echocardiographic parameters: Presence and quantification of a valvular regurgitation
Measure: Ultrasound characteristics. Time: 1 yearDescription: Describe at the admission and during the treatment ultrasound characteristics of the acute myocarditis among the positive and negative SARS-Cov-2 patients of the myocarditis cohort ; Echocardiographic parameters: Presence of a pericardial effusion
Measure: Ultrasound characteristics. Time: 1 yearDescription: Assess the short-term (30 days) and long-term (1 year) prognosis of the acute myocarditis among the positive and negative SARS-Cov-2 patients of the myocarditis cohort. The 30-day prognosis will be defined in function to the outcome: A death, whatever the cause, A cardiovascular arrest with recovery, A cardiogenic shock, An acute lung oedema or One of the events cited above. The 1-year prognosis will be defined in function to the outcome: A death, whatever the cause, The need to resort to transplantation and/or chronic assistance, A rehospitalization for cardiovascular reasons (heart failure, painful relapse, recovered cardiac arrest, myocarditis relapse, ACS), A myocarditis relapse, or one of the events cited above. The 1-year prognosis will also be defined in function to the New York Heart Association (NYHA) class.
Measure: Assess prognosis of the acute myocarditis . Time: The short-term (30 days) and long-term (1 year).Description: Identify the factors associated with a 30-day and 1-year prognosis of cases of acute myocarditis cardiovascular (Terminal heart failure, Acute edema of the lung, Cardiogenic shock, Sudden death / Ventricular rhythm disorder Pulmonary embolism, Aortic dissection Infectious endocarditis Stroke) or no cardiovascular (Acute respiratory syndrome, septic shock of non-cardiac origin, cancer, Public road accident, end-stage respiratory failure, insufficiency, end-stage renal Failure)
Measure: The factors associated with acute myocarditis cases . Time: The short-term (30 days) and long-term (1 year).Description: Describe the biological parameters on admission and during the treatment (troponinemia (ng/ml)
Measure: Biological characteristics Time: 1 yearDescription: Describe the biological parameters on admission and during the treatment NtproBNP(pg/ml)
Measure: Biological characteristics Time: 1 yearDescription: Describe the biological parameters on admission and during the treatment CRP(mg/ml)
Measure: Biological characteristics Time: 1 yearDescription: Ventricular volumes (ml)
Measure: Describe at the admission and during the treatment cardiac MRI parameters Time: 1 yearDescription: Systole Diameter
Measure: Describe at the admission and during the treatment cardiac MRI parameters Time: 1 yearDescription: Diastole Diameter
Measure: Describe at the admission and during the treatment cardiac MRI parameters Time: 1 yearDescription: Longitudinal deformation of left ventricle;
Measure: Describe at the admission and during the treatment cardiac MRI parameters Time: 1 yearDescription: Longitudinal deformation of right ventricle;
Measure: Describe at the admission and during the treatment cardiac MRI parameters Time: 1 yearDescription: Total volume of left ventricular oedema
Measure: Describe at the admission and during the treatment cardiac MRI parameters Time: 1 yearDescription: Quantification of T2 before contrast agent
Measure: Describe at the admission and during the treatment cardiac MRI parameters Time: 1 yearDescription: Quantification of T1 before contrast agent
Measure: Describe at the admission and during the treatment cardiac MRI parameters Time: 1 yearDescription: Perfusion anomalies
Measure: Describe at the admission and during the treatment cardiac MRI parameters Time: 1 yearDescription: Total volume of early left ventricular alteration
Measure: Describe at the admission and during the treatment cardiac MRI parameters Time: 1 yearDescription: Total volume of late left ventricular alteration
Measure: Describe at the admission and during the treatment cardiac MRI parameters Time: 1 yearDescription: Quantification of T1 after contrast agent
Measure: Describe at the admission and during the treatment cardiac MRI parameters Time: 1 yearDescription: Presence of a pericardial effusion
Measure: Describe at the admission and during the treatment cardiac MRI parameters Time: 1 yearAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports